<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33605">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093819</url>
  </required_header>
  <id_info>
    <org_study_id>1345.1</org_study_id>
    <secondary_id>2013-003560-31</secondary_id>
    <nct_id>NCT02093819</nct_id>
  </id_info>
  <brief_title>To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers and Investigate Relative Bioavailability of BI 416970 as Well as Assess of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 416970 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, Investigation of Relative Bioavailability of BI 416970 (Open-label, Randomised, Three-way Cross-over) and Assessment of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers (Open-label, Single-dose)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics
      (PK) of single rising doses of BI 416970. A further objective is to explore the relative
      bioavailability of tablet fasted versus PfOS fasted and of tablet fasted versus tablet fed
      and to assess the influence of CYP2C9 phenotype on the PK of BI 416970.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with drug-related adverse events</measure>
    <time_frame>up to 7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 416970 single rising dose part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising dose given as tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 416970 bioavailability part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given as tablet and solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 416970 geno-part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given as tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 416970</intervention_name>
    <description>geno-part</description>
    <arm_group_label>BI 416970 geno-part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 416970</intervention_name>
    <description>different dose formulations</description>
    <arm_group_label>BI 416970 bioavailability part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 416970</intervention_name>
    <description>single rising doses</description>
    <arm_group_label>BI 416970 single rising dose part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 416970</intervention_name>
    <description>single rising doses</description>
    <arm_group_label>BI 416970 single rising dose part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy males according to the investigator's assessment, based on a complete medical
             history including a physical examination, vital signs (Blood Pressure, Pulse Rate),
             12-lead electrocardiogram, and clinical laboratory

          -  Age 18 to 50 years (incl.)

          -  Body Mass Index 18.5 to 29.9 kg/m2 (incl.)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

          -  Known genotype of CYP2C9 isoenzyme

        Exclusion criteria:

          -  Any finding in the medical examination (including Blood Pressure, Pulse Rate or
             Electrocardiogram) is deviating from normal and judged as clinically relevant by the
             investigator

          -  Repeated measurement of systolic blood pressure greater than 140 mmHg, diastolic
             blood pressure greater than 90 mmHg, or pulse rate outside the range of 50 to 90 mmHg

          -  Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance

          -  Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial
             medication

          -  Diseases of the central nervous system (such as epilepsy), other peripheral
             neurological disorders or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1345.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
